New trends in the management of cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a survey of the Infectious Diseases Working Pary of EBMT.
New trends in the management of cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a survey of the Infectious Diseases Working Pary of EBMT.
复制标题
DOI：
10.1038/s41409-022-01863-8
复制
发表时间：
2023-02
影响因子：
4.8
通讯作者：
de la Camara, Rafael
中科院分区：
文献类型：
--
作者：
Cesaro, Simone;Ljungman, Per;Tridello, Gloria;Mikulska, Malgorzata;Wendel, Lotus;Styczynski, Jan;Averbuch, Dina;de la Camara, Rafael
巨细胞病毒（CMV）感染的管理由欧洲血液和骨髓移植学会（EBMT）传染病工作组于2020年进行的调查进行评估。579个EBMT中心中有180个（31%）做出了回应。97%的中心使用CMV-DNA血症定量PCR监测CMV，而监测持续时间根据患者免疫恢复和正在进行的免疫抑制治疗而变化。101个中心（56%）对高危患者进行了CMV预防：62个中心（61%）使用了莱特莫韦，19个中心（19%）使用了阿昔洛韦/伐昔洛韦，17个中心（17%）使用了更昔洛韦/伐更昔洛韦，3个中心（3%）使用了膦甲酸。最常用的先发制人治疗的触发阈值是>103拷贝/ml或>103 IU/ml。更昔洛韦/缬更昔洛韦证实了预防性和CMV疾病治疗的首选一线治疗。CMV-细胞毒性T细胞主要用于复发性/难治性CMV疾病。48个中心报告了由于突变的CMV毒株引起的CMV难治性/耐药感染。这项调查显示，半数以上的中心采用预防方法预防CMV感染。莱特莫韦预防如何改变日常CMV管理的其他重要支柱，如CMV-DNA血症监测和先发制人治疗的频率，仍然是一个调查问题。
The management of cytomegalovirus (CMV) infection was assessed with a survey performed in 2020 by the Infectious Diseases Working Party of European Society for Blood and Marrow Transplantation (EBMT). One-hundred-eighty of the 579 EBMT centres (31%) responded. CMV monitoring with quantitative PCR for CMV-DNAemia was used by 97% of centres while the duration of monitoring was variable according to the patient immune recovery and the ongoing immunosuppressive therapy. CMV prophylaxis for high-risk patients was used in 101 (56%) of centres: letermovir in 62 centres (61%), aciclovir/valaciclovir in 19 centres (19%), ganciclovir/valganciclovir in 17 centres (17%), foscarnet in 3 (3%). The most used trigger for pre-emptive therapy was a threshold of >103 copies/ml or >103 IU/ml. Ganciclovir/valganciclovir confirmed the preferred first line treatment both for pre-emptive and CMV disease therapy. CMV-cytotoxic T-cells were used mainly in the setting of relapsing/refractory CMV disease. Forty-eight centres reported CMV refractory/resistant infection due to mutated CMV strain.This survey showed that letermovir prophylaxis is adopted by more than half of centres using a prophylaxis approach for CMV infection. How letermovir prophylaxis will modify other important pillars of daily CMV management, such as frequency of CMV-DNAemia monitoring and preemptive therapy, remain a matter of investigation.
登录
查看更多内容
影响因子：
4.3
作者：
Green, Margaret L.;Leisenring, Wendy;Stachel, Daniel;Pergam, Steven A.;Sandmaier, Brenda M.;Wald, Anna;Corey, Lawrence;Boeckh, Michael
通讯作者：
Boeckh, Michael
影响因子：
11.8
作者：
Ljungman, Per;Boeckh, Michael;Griffiths, Paul D.
通讯作者：
Griffiths, Paul D.
影响因子：
3.2
作者：
Olson, Amanda L.;Politikos, Ioannis;Hill, Joshua A.
通讯作者：
Hill, Joshua A.
DOI：
10.4084/mjhid.2016.031
发表时间：
2016
影响因子：
3.2
作者：
de la Cámara R
通讯作者：
de la Cámara R
影响因子：
158.5
作者：
Marty, F. M.;Ljungman, P.;Badshah, C.
通讯作者：
Badshah, C.